Erratum to anti-GD2 CAR T cells could prove transformative for H3-K27M⁺ diffuse midline gliomas

Anti-GD2 CAR T cells could prove transformative for H3-K27M⁺ diffuse midline gliomas

In the March 2019 supplement issue (V8S2) of Translational Cancer Research, the paper “Anti-GD2 CAR T cells could prove transformative for H3-K27M⁺ diffuse midline gliomas”, 2019 Mar;8(Suppl 2):S87-S93, by Koichi Furukawa, Yuhsuke Ohmi and Keiko Furukawa (1), was published with some errors and should be corrected as below:

1. The small part on the left of Figure 2 was involved mistakenly and should be removed, and whole Figure 2 should be corrected as:

2. The word “CAR-T” in the third paragraph of “Systemic injection of anti-GD2 CAR T cells were well transferred to CNS and demonstrated great elimination of GD2 DMG xenografts” section should be corrected as “CAR T”.

3. In the first paragraph of “Modes of action of disialyl gangliosides in cancer cells” section, “(PDGFR)” should be changed to “(PDGFR)α”, “PDGFR” should be changed to “PDGFRα”, and “PAGFR” should be changed to “PDGFRα”.

Figure 2.

Anti-GD2 CAR T cells are promising approach to treat DIPG. Anti-GD2 CAR T cells could infiltrate into glioma tissues, and eliminate almost completely GD2-expressing cells after systemic injection (left). In contrast, anti-GD2 mAbs are hard to access glioma cells by crossing the blood brain barrier (right). This may be also the case in anti-immune check-point antibodies. DIPG, diffuse intrinsic pontine glioma.

The authors regret the errors and all the inconveniences caused.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.